Published in Clin Cancer Res on April 01, 2008
Acromegaly pathogenesis and treatment. J Clin Invest (2009) 2.19
Epigenetic control of sexual differentiation of the bed nucleus of the stria terminalis. Endocrinology (2009) 1.35
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget (2015) 1.07
MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ (2011) 0.96
Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients. Clin Cancer Res (2014) 0.90
Retracted Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol (2010) 0.87
Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma. Oncoimmunology (2014) 0.87
Exposure of Human Prostaspheres to Bisphenol A Epigenetically Regulates SNORD Family Noncoding RNAs via Histone Modification. Endocrinology (2015) 0.85
The molecular pathogenesis of pituitary adenomas: an update. Endocrinol Metab (Seoul) (2013) 0.85
Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int J Cancer (2009) 0.84
An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. BMC Cancer (2011) 0.84
The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol (2012) 0.82
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer (2013) 0.82
Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach. Mol Cell Endocrinol (2010) 0.81
The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature. PLoS One (2013) 0.79
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. J Mol Biol (2017) 0.75
Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol (2014) 0.75
The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol (2005) 6.43
Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer (2006) 3.83
The prevalence of pituitary adenomas: a systematic review. Cancer (2004) 2.98
Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid (2009) 2.79
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Hum Pathol (2009) 2.54
Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med (2014) 2.31
Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. Am J Pathol (2003) 2.29
Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol (2008) 2.21
Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol (2004) 2.08
The pathogenesis of pituitary tumours. Nat Rev Cancer (2002) 1.96
Diagnosis and management of hyperprolactinemia. CMAJ (2003) 1.85
Thyroid calcification and its association with thyroid carcinoma. Head Neck (2002) 1.70
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res (2008) 1.53
EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer (2011) 1.50
The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. Cell Metab (2013) 1.45
Pseudopheochromocytoma of pregnancy. Endocr Pract (2003) 1.45
Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol (2005) 1.41
Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol (2002) 1.39
The pathogenesis of pituitary tumors. Annu Rev Pathol (2009) 1.38
"Next-generation" pathology and laboratory medicine. Arch Pathol Lab Med (2011) 1.38
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab (2008) 1.37
Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology (2004) 1.31
AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract (2004) 1.27
Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 1.26
The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev (2006) 1.24
Retracted Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest (2002) 1.24
XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol (2010) 1.21
Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med (2008) 1.20
Carney complex with adrenal cortical carcinoma. J Clin Endocrinol Metab (2011) 1.19
Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis (2004) 1.18
Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res (2009) 1.18
Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res (2008) 1.17
Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res (2007) 1.16
Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis (2004) 1.16
Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest (2002) 1.15
A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res (2011) 1.14
Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg (2003) 1.14
Papillary thyroid carcinoma: an overview. Arch Pathol Lab Med (2006) 1.13
Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab (2011) 1.13
Clinicopathological correlations in pituitary adenomas. Brain Pathol (2012) 1.12
The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. PLoS One (2009) 1.11
Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord (2008) 1.07
Correlation of biochemical parameters with single parathyroid adenoma weight and volume. Head Neck (2002) 1.07
Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab (2002) 1.06
Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol (2002) 1.05
Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid (2010) 1.04
Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol (2011) 1.04
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood (2007) 1.03
Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid (2007) 1.03
Mechanisms of disease: The pathogenesis of pituitary tumors. Nat Clin Pract Endocrinol Metab (2006) 1.02
Follicular variant papillary thyroid carcinoma arising in struma ovarii. Endocr Pathol (2007) 1.02
The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab (2005) 1.01
Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol (2009) 1.00
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol (2007) 1.00
Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol (2009) 0.99
Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol (2007) 0.99
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) (2009) 0.98
Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol (2009) 0.98
Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol (2012) 0.97
Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases. Arch Pathol Lab Med (2008) 0.97
A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) (2008) 0.96
Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab (2002) 0.96
The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res (2007) 0.96
Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest (2005) 0.96
Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. Eur J Immunol (2007) 0.96
IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol (Oxf) (2004) 0.95
Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J Biol Chem (2003) 0.95
Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res (2005) 0.95
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol (Oxf) (2012) 0.95
Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. Mol Endocrinol (2002) 0.94
A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) (2007) 0.92
The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet (2011) 0.92
Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol (2007) 0.92
The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res (2012) 0.92
Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol (2003) 0.91
Completion thyroidectomy versus total thyroidectomy: is there a difference in complication rates? An analysis of 350 patients. J Am Coll Surg (2007) 0.91